This book is a printed edition of the Special Issue "The Tumor Microenvironment of High Grade Serous Ovarian Cancer" that was published in Cancers
In addition to these cells of the TME, the role of various cellular factors made by the cells of the TME are also the subject of the reviews.
Research areas covered include therapy response and development, microenvironmental influences and the etiology and progression of EOC. Ten articles detail established and novel in vivo and in vitro model systems.
This book provides an overview of the latest developments in the concepts and management of ovarian cancer. The new data presented throughout opens the way to radically different therapeutic approaches.
... PharmD Volume 8: Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies Edited by Chi Hin Cho and Tao Hu, PhD Volume 9: Novel Therapies in Head and Neck Cancer: Beyond the Horizon Edited by Maie A. St.
In the long term, our studies will broaden the understanding of the mechanism of CSC maintenance by the tumor microenvironment and contribute towards the development of novel therapeutic approaches to prevent ovarian cancer chemoresistance ...
Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines ...
This book summarizes the important developments in the field of cancer research, specifically uterine cervical/endometrial cancer and ovarian cancer.
This detailed volume provides a robust set of methods to understand variation between patients with ovarian cancers, in vitro models to better study different stages of the disease, and in vivo models to test therapies.
with end of life interventions and direct hospital costs. Gynecol Oncol 2014; 132(1):3–7. 20. Zakhour M, LaBrant L, Rimel BJ, et al. Too much, too late: aggressive measures and the timing of end of life care discussions in women with ...
Another important protein on the T cell, which if bound and activated can suppress an immune response, is cytotoxic ... Food and Drug Administration (USA); Ig, immunoglobulin; NSCLC, non-small-cell lung cancer; PD-1, programmed cell ...